Find Denfivontinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

0

USDMF

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

NDC API

0

VMF

0

Listed Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

0

FDA Orange Book

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1457983-28-6, G-749, 8-bromo-2-((1-methylpiperidin-4-yl)amino)-4-((4-phenoxyphenyl)amino)pyrido[4,3-d]pyrimidin-5(6h)-one, 8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-(4-phenoxyanilino)-6h-pyrido[4,3-d]pyrimidin-5-one, Unii-b06w426b66, 8-bromo-2-((1-methylpiperidin-4-yl)amino)-4-((4-phenoxyphenyl)amino)pyrido(4,3-d)pyrimidin-5(6h)-one
Molecular Formula
C25H25BrN6O2
Molecular Weight
521.4  g/mol
InChI Key
SXWMIXPJPNCXQQ-UHFFFAOYSA-N
FDA UNII
B06W426B66

Denfivontinib
Denfivontinib is an orally bioavailable inhibitor of both wild type and mutant forms of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon administration, denfivontinib binds to and inhibits the activity of FLT3, including FLT3-ITD (internal tandem duplications), FLT3-D835Y as well as other mutants. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemias, and plays a key role in tumor cell proliferation. In addition, denfivontinib also inhibits, to a lesser degree, the receptor tyrosine kinases AXL (UFO), Mer, Ret, vascular endothelial growth factor receptor 1 (VEGFR1), Fms, fibroblast growth factor receptors (FGFR) 1 and 3, and the serine/threonine kinases Aurora B and C.
1 2D Structure

Denfivontinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-(4-phenoxyanilino)-6H-pyrido[4,3-d]pyrimidin-5-one
2.1.2 InChI
InChI=1S/C25H25BrN6O2/c1-32-13-11-17(12-14-32)29-25-30-22-20(26)15-27-24(33)21(22)23(31-25)28-16-7-9-19(10-8-16)34-18-5-3-2-4-6-18/h2-10,15,17H,11-14H2,1H3,(H,27,33)(H2,28,29,30,31)
2.1.3 InChI Key
SXWMIXPJPNCXQQ-UHFFFAOYSA-N
2.2 Other Identifiers
2.2.1 UNII
B06W426B66
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 1457983-28-6

2. G-749

3. 8-bromo-2-((1-methylpiperidin-4-yl)amino)-4-((4-phenoxyphenyl)amino)pyrido[4,3-d]pyrimidin-5(6h)-one

4. 8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-(4-phenoxyanilino)-6h-pyrido[4,3-d]pyrimidin-5-one

5. Unii-b06w426b66

6. 8-bromo-2-((1-methylpiperidin-4-yl)amino)-4-((4-phenoxyphenyl)amino)pyrido(4,3-d)pyrimidin-5(6h)-one

7. 8-bromo-2-((1-methylpiperidin-4-yl)amino)-4-(4-phenoxyanilino)-6h-pyrido(4,3-d)pyrimidin-5-one

8. Refchem:131866

9. G-801

10. G749

11. Pyrido[4,3-d]pyrimidin-5(6h)-one, 8-bromo-2-[(1-methyl-4-piperidinyl)amino]-4-[(4-phenoxyphenyl)amino]-

12. B06w426b66

13. 8-bromo-2-[(1-methyl-4-piperidinyl)amino]-4-[(4-phenoxyphenyl)amino]pyrido[4,3-d]pyrimidin-5(6h)-one

14. C25h25brn6o2

15. Mfcd28167815

16. Denfivontinib [inn]

17. Gtpl8108

18. Orb1305257

19. Chembl4544478

20. Schembl15265027

21. Schembl30471308

22. Bdbm756196

23. Glxc-90053

24. Ex-a1074

25. Bdbm50422751

26. S7545

27. Us12350272, Compound 226

28. Akos026750566

29. Ccg-269863

30. Cs-3343

31. Ebc-220145

32. Ncgc00386412-04

33. Ac-33000

34. Bs-15433

35. Da-33613

36. Hy-12333

37. G-749?

38. Q27077763

39. 38-bromo-11-methyl-6-oxa-2,4-diaza-3(2,4)-pyrido[4,3-d]pyrimidina-1(4)-piperidina-5(1,4),7(1)-dibenzenaheptaphan-35(36h)-one

40. 8-bromo-2-[(1-methyl-4-piperidyl)amino]-4-(4-phenoxyanilino)-6h-pyrido[4,3-d]pyrimidin-5-one

41. 8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-[(4-phenoxyphenyl)amino]-5h,6h-pyrido[4,3-d]pyrimidin-5-one

2.4 Create Date
2014-10-10
3 Chemical and Physical Properties
Molecular Weight 521.4 g/mol
Molecular Formula C25H25BrN6O2
XLogP34.9
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count7
Rotatable Bond Count6
Exact Mass Da
Monoisotopic Mass Da
Topological Polar Surface Area91.4
Heavy Atom Count34
Formal Charge0
Complexity716
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Looking for 1457983-28-6 / Denfivontinib API manufacturers, exporters & distributors?

Denfivontinib manufacturers, exporters & distributors 1

25

PharmaCompass offers a list of Denfivontinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Denfivontinib manufacturer or Denfivontinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Denfivontinib manufacturer or Denfivontinib supplier.

API | Excipient name

Denfivontinib

Synonyms

1457983-28-6, G-749, 8-bromo-2-((1-methylpiperidin-4-yl)amino)-4-((4-phenoxyphenyl)amino)pyrido[4,3-d]pyrimidin-5(6h)-one, 8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-(4-phenoxyanilino)-6h-pyrido[4,3-d]pyrimidin-5-one, Unii-b06w426b66, 8-bromo-2-((1-methylpiperidin-4-yl)amino)-4-((4-phenoxyphenyl)amino)pyrido(4,3-d)pyrimidin-5(6h)-one

Cas Number

1457983-28-6

Unique Ingredient Identifier (UNII)

B06W426B66

About Denfivontinib

Denfivontinib is an orally bioavailable inhibitor of both wild type and mutant forms of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon administration, denfivontinib binds to and inhibits the activity of FLT3, including FLT3-ITD (internal tandem duplications), FLT3-D835Y as well as other mutants. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemias, and plays a key role in tumor cell proliferation. In addition, denfivontinib also inhibits, to a lesser degree, the receptor tyrosine kinases AXL (UFO), Mer, Ret, vascular endothelial growth factor receptor 1 (VEGFR1), Fms, fibroblast growth factor receptors (FGFR) 1 and 3, and the serine/threonine kinases Aurora B and C.

Denfivontinib Manufacturers

A Denfivontinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Denfivontinib, including repackagers and relabelers. The FDA regulates Denfivontinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Denfivontinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Denfivontinib Suppliers

A Denfivontinib supplier is an individual or a company that provides Denfivontinib active pharmaceutical ingredient (API) or Denfivontinib finished formulations upon request. The Denfivontinib suppliers may include Denfivontinib API manufacturers, exporters, distributors and traders.

Denfivontinib GMP

Denfivontinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Denfivontinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Denfivontinib GMP manufacturer or Denfivontinib GMP API supplier for your needs.

Denfivontinib CoA

A Denfivontinib CoA (Certificate of Analysis) is a formal document that attests to Denfivontinib's compliance with Denfivontinib specifications and serves as a tool for batch-level quality control.

Denfivontinib CoA mostly includes findings from lab analyses of a specific batch. For each Denfivontinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Denfivontinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Denfivontinib EP), Denfivontinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Denfivontinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty